ProstaLund AB (publ) Logo

ProstaLund AB (publ)

PLUN.ST

(1.5)
Stock Price

0,24 SEK

-86.16% ROA

-41.65% ROE

-1.29x PER

Market Cap.

40.672.197,00 SEK

11.92% DER

0% Yield

-123.16% NPM

ProstaLund AB (publ) Stock Analysis

ProstaLund AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ProstaLund AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (2%), which means it has a small amount of debt compared to the ownership it holds

2 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 PBV

The stock's PBV ratio (1.99x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-26.61%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-24.16%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-3) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

ProstaLund AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ProstaLund AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

ProstaLund AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ProstaLund AB (publ) Revenue
Year Revenue Growth
2012 7.654.000
2013 8.614.000 11.14%
2014 9.613.000 10.39%
2015 13.613.000 29.38%
2016 14.612.000 6.84%
2017 13.544.000 -7.89%
2018 13.567.000 0.17%
2019 12.886.000 -5.28%
2020 12.465.000 -3.38%
2021 17.073.000 26.99%
2022 17.411.000 1.94%
2023 19.248.000 9.54%
2023 22.206.000 13.32%
2024 11.264.000 -97.14%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ProstaLund AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 668.000 100%
2014 784.000 14.8%
2015 730.000 -7.4%
2016 860.000 15.12%
2017 1.210.000 28.93%
2018 1.831.000 33.92%
2019 2.834.000 35.39%
2020 3.874.000 26.85%
2021 3.244.000 -19.42%
2022 4.000.000 18.9%
2023 4.228.000 5.39%
2023 4.923.000 14.12%
2024 6.884.000 28.49%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ProstaLund AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 3.030.000
2013 3.548.000 14.6%
2014 4.929.000 28.02%
2015 5.381.000 8.4%
2016 3.626.000 -48.4%
2017 6.383.000 43.19%
2018 6.962.000 8.32%
2019 7.429.000 6.29%
2020 6.200.000 -19.82%
2021 6.809.000 8.94%
2022 5.513.000 -23.51%
2023 10.564.000 47.81%
2023 9.316.000 -13.4%
2024 13.400.000 30.48%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ProstaLund AB (publ) EBITDA
Year EBITDA Growth
2012 -2.507.000
2013 -4.266.000 41.23%
2014 -7.362.000 42.05%
2015 -8.845.000 16.77%
2016 -10.167.000 13%
2017 -16.147.000 37.03%
2018 -12.556.000 -28.6%
2019 -10.209.000 -22.99%
2020 -9.750.000 -4.71%
2021 -7.542.000 -29.28%
2022 -10.670.000 29.32%
2023 -24.980.000 57.29%
2023 -16.306.999 -53.19%
2024 -28.396.000 42.57%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ProstaLund AB (publ) Gross Profit
Year Gross Profit Growth
2012 5.479.000
2013 6.043.000 9.33%
2014 7.151.000 15.49%
2015 7.633.000 6.31%
2016 8.832.000 13.58%
2017 9.005.000 1.92%
2018 8.120.000 -10.9%
2019 8.995.000 9.73%
2020 9.545.000 5.76%
2021 14.683.000 34.99%
2022 12.873.000 -14.06%
2023 14.088.000 8.62%
2023 15.387.000 8.44%
2024 8.348.000 -84.32%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ProstaLund AB (publ) Net Profit
Year Net Profit Growth
2012 -561.000
2013 -4.645.000 87.92%
2014 -7.786.000 40.34%
2015 -9.373.000 16.93%
2016 -11.974.000 21.72%
2017 -16.894.000 29.12%
2018 -12.950.000 -30.46%
2019 -10.728.000 -20.71%
2020 -10.041.000 -6.84%
2021 -7.919.000 -26.8%
2022 -11.303.000 29.94%
2023 -25.136.000 55.03%
2023 -17.010.000 -47.77%
2024 -28.836.000 41.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ProstaLund AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 -1 0%
2014 -1 100%
2015 -1 0%
2016 -1 0%
2017 -1 100%
2018 -1 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ProstaLund AB (publ) Free Cashflow
Year Free Cashflow Growth
2012 -4.836.000
2013 -4.584.000 -5.5%
2014 -11.369.000 59.68%
2015 -10.715.000 -6.1%
2016 -15.747.000 31.96%
2017 -19.088.000 17.5%
2018 -13.218.000 -44.41%
2019 -11.289.000 -17.09%
2020 -12.051.000 6.32%
2021 -14.991.000 19.61%
2022 -20.956.000 28.46%
2023 -12.683.000 -65.23%
2023 -27.146.000 53.28%
2024 -7.494.000 -262.24%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ProstaLund AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2012 -2.605.000
2013 -3.875.000 32.77%
2014 -10.834.000 64.23%
2015 -9.750.000 -11.12%
2016 -14.407.000 32.32%
2017 -16.114.000 10.59%
2018 -11.893.000 -35.49%
2019 -9.115.000 -30.48%
2020 -8.581.000 -6.22%
2021 -5.804.000 -47.85%
2022 -16.202.000 64.18%
2023 -12.107.000 -33.82%
2023 -23.801.000 49.13%
2024 -6.089.000 -290.89%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ProstaLund AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2012 2.231.000
2013 709.000 -214.67%
2014 535.000 -32.52%
2015 965.000 44.56%
2016 1.340.000 27.99%
2017 2.974.000 54.94%
2018 1.325.000 -124.45%
2019 2.174.000 39.05%
2020 3.470.000 37.35%
2021 9.187.000 62.23%
2022 4.754.000 -93.25%
2023 576.000 -725.35%
2023 3.345.000 82.78%
2024 1.405.000 -138.08%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ProstaLund AB (publ) Equity
Year Equity Growth
2012 4.690.000
2013 5.234.000 10.39%
2014 11.886.000 55.97%
2015 23.193.000 48.75%
2016 30.811.000 24.72%
2017 13.774.000 -123.69%
2018 12.711.000 -8.36%
2019 22.233.000 42.83%
2020 25.352.000 12.3%
2021 35.456.000 28.5%
2022 41.686.000 14.95%
2023 55.291.000 24.61%
2023 58.696.000 5.8%
2024 43.321.000 -35.49%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ProstaLund AB (publ) Assets
Year Assets Growth
2012 6.914.000
2013 9.611.000 28.06%
2014 15.856.000 39.39%
2015 27.102.000 41.5%
2016 35.232.000 23.08%
2017 17.924.000 -96.56%
2018 19.156.000 6.43%
2019 26.389.000 27.41%
2020 30.837.000 14.42%
2021 43.480.000 29.08%
2022 51.043.000 14.82%
2023 65.507.000 22.08%
2023 68.716.000 4.67%
2024 55.815.000 -23.11%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ProstaLund AB (publ) Liabilities
Year Liabilities Growth
2012 2.223.000
2013 4.377.000 49.21%
2014 3.970.000 -10.25%
2015 3.909.000 -1.56%
2016 4.421.000 11.58%
2017 4.149.000 -6.56%
2018 6.445.000 35.62%
2019 4.157.000 -55.04%
2020 5.485.000 24.21%
2021 8.024.000 31.64%
2022 9.357.000 14.25%
2023 10.216.000 8.41%
2023 10.020.000 -1.96%
2024 12.494.000 19.8%

ProstaLund AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.23
Net Income per Share
-0.28
Price to Earning Ratio
-1.29x
Price To Sales Ratio
2.31x
POCF Ratio
-0.92
PFCF Ratio
-1.15
Price to Book Ratio
0.65
EV to Sales
2.42
EV Over EBITDA
-1.98
EV to Operating CashFlow
-1.4
EV to FreeCashFlow
-1.2
Earnings Yield
-0.77
FreeCashFlow Yield
-0.87
Market Cap
0,04 Bil.
Enterprise Value
0,04 Bil.
Graham Number
1.9
Graham NetNet
0.04

Income Statement Metrics

Net Income per Share
-0.28
Income Quality
1.41
ROE
-0.42
Return On Assets
-0.39
Return On Capital Employed
-0.51
Net Income per EBT
1
EBT Per Ebit
0.96
Ebit per Revenue
-1.28
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.68
Research & Developement to Revenue
0.34
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.73
Operating Profit Margin
-1.28
Pretax Profit Margin
-1.23
Net Profit Margin
-1.23

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.4
Free CashFlow per Share
-0.46
Capex to Operating CashFlow
-0.16
Capex to Revenue
0.28
Capex to Depreciation
29.5
Return on Invested Capital
-0.48
Return on Tangible Assets
-0.86
Days Sales Outstanding
115.92
Days Payables Outstanding
454.14
Days of Inventory on Hand
1165.01
Receivables Turnover
3.15
Payables Turnover
0.8
Inventory Turnover
0.31
Capex per Share
0.07

Balance Sheet

Cash per Share
0,04
Book Value per Share
0,57
Tangible Book Value per Share
0.16
Shareholders Equity per Share
0.57
Interest Debt per Share
0.07
Debt to Equity
0.12
Debt to Assets
0.09
Net Debt to EBITDA
-0.08
Current Ratio
2.06
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
43590000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.55
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
15624500
Debt to Market Cap
0.13

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ProstaLund AB (publ) Dividends
Year Dividends Growth

ProstaLund AB (publ) Profile

About ProstaLund AB (publ)

ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.

CEO
Mr. Anders Kristensson
Employee
9
Address
Mobilvägen 10
Lund, 223 62

ProstaLund AB (publ) Executives & BODs

ProstaLund AB (publ) Executives & BODs
# Name Age
1 Mr. Niclas Nystroom
Chief Financial Officer
70
2 Mr. Anders Kristensson
Chief Executive Officer
70
3 Mr. Johan Laven
Director of Sales & Marketing
70
4 Ms. Charlotta Andersson
Sales Manager and Clinical Instructor - Sweden & Finland
70
5 Ms. Erika Carlsson
Chief Operating Officer
70

ProstaLund AB (publ) Competitors